Related coverage linked through entity extraction aliases.
Mar 16, 2026
Multiple institutional investors expanded their positions in AstraZeneca during the third quarter of 2025, with several funds increasing holdings by over 100% according to SEC filings.
Feb 23, 2026
Multiple institutional investors expanded their stakes in AstraZeneca during the third quarter of 2025, with the stock trading near its 52-week high and maintaining a "Moderate Buy" rating from analysts.
Feb 14, 2026
Multiple institutional investors modified their positions in AstraZeneca during the third quarter, with new stakes and adjustments reported in SEC filings. The company announced a dividend of $1.595 per share payable March 23rd.
Feb 13, 2026
Moderna reported Q4 revenue of $678 million, beating analyst estimates, while posting a narrower-than-expected loss of $2.11 per share. The results came as the FDA refused to review the company's mRNA flu vaccine application.
